Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with Chemotherapy in Infants with KMT2A-Rearranged ALL
NCT02828358Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Primary endpoint: Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy at 6 months. Started Apr 2017; status: completed.
02
Drugs
azacitidine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02828358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828358.